WILEX AG successfully completes rights issue
Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)
Munich, Germany, 01 February 2012. The shareholders of WILEX AG (ISIN DE0006614720/WL6/FSE) exercised their subscription and oversubscription rights for all of the 3,201,928 new no-par value bearer shares for EUR 3.10 per share by the end of the subscription period on 30 January 2012. As a result, the Executive Management Board today resolved with the approval of the Supervisory Board to set the total volume of the rights issue at 3,201,928 new shares.
Shareholders exercised subscription rights for a total of 2,417,077 new shares, which corresponds to a subscription ratio of more than 75%. The Company’s main shareholders – dievini Hopp BioTech holding GmbH & Co. KG, Verwaltungsgesellschaft des Golf Club St. Leon-Rot mbH and UCB Pharma S.A. – exercised all of their subscription rights.
A total of 784,851 shares were available under shareholders‘ oversubscription rights which have been placed with full allocation to the shareholders through the custodian banks. Approximately 68 % of the oversubscription was assigned to shareholders within the free float.
WILEX AG plans to use the gross proceeds of approximately € 9.93 million from the rights issue to finance its ongoing clinical studies and continued growth as well as to enhance its equity position.
Following the entry of the capital increase in the Commercial Register – which is scheduled for 3 February 2012 – the total number of WILEX shares issued will increase to 24,814,963. The subscribed and allocated new WILEX shares are expected to be delivered on 6 February 2012, after they have been listed on the stock exchange in the regulated market (Prime Standard). Trading of the new shares on the stock exchange is also scheduled to commence on 6 February 2012. Due to the different dividend entitlement the new shares will be traded separately with the ISIN DE000A1MMAS8 until the planned inclusion of the new shares in the existing stock exchange listing (after the AGM on 25 May 2012). The sole lead manager of the transaction was Landesbank Baden-Württemberg, Stuttgart (LBBW).
+++ End of ad-hoc release +++
About WILEX AG
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the company has a broad portfolio of near-to-market therapeutic and diagnostic products for the targeted treatment and specific detection of various types of cancer. The company’s therapeutic product candidates are based on antibodies and small molecules. Through its US subsidiary WILEX Inc. in Cambridge, MA, WILEX markets a portfolio of research use only and in vitro diagnostic tests under the brand Oncogene Science. These diagnostic tests could be developed as companion diagnostics in clinical trials and for therapy monitoring. The wholly owned subsidiary Heidelberg Pharma GmbH gives WILEX access to an attractive and highly promising antibody drug conjugate technology platform and a pre-clinical service business. The business model of WILEX covers the entire value chain in the oncology market and comprises research, technology, development collaboration as well as sales and marketing. WILEX’s customers and partners include leading international pharmaceutical companies. ISIN DE0006614720 / WKN 661472 / Symbol WL6
Katja Arnold (CIRO)
81675 Munich; Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.